Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy

References

• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Franklin SS. Hypertension in older people: part 2. J Clin Hypertens (Greenwich) 2006;8:521-25
   PubMedGoogle Scholar
• Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults, 1999–2004. Hypertension 2007;49:69-75
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003;290:199-206
   PubMed Web of Science ®Google Scholar
• Cook NR, Cohen J, Hebert PR, et al. Implication of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701-09
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62
   PubMed Web of Science ®Google Scholar
• Milani RV. Reaching for aggressive blood pressure goals: Role of angiotensin receptor blockade in combination therapy. Am J Manag Care 2005;11:S220-27
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404
   PubMedGoogle Scholar
• Cifkova R, Erdine S, Fagard R, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003;21:1779-86
   PubMedGoogle Scholar
• Weber MA. Creating a combination antihypertensive regimen: what does the research show?. J Clin Hypertens (Greenwich) 2003;5:12-20
   PubMedGoogle Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-62
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Aksnes TA, de la Sierra A, et al. Amlodipine and valsartan: Calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy 2007;4:31-40
   Google Scholar
• Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4
   PubMed Web of Science ®Google Scholar
• Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild-to-moderate essential hypertension. Clin Ther 2007;29:563-80
   PubMed Web of Science ®Google Scholar
• Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495-501
   PubMed Web of Science ®Google Scholar
• Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens 2004;6:621-31
   PubMedGoogle Scholar
• Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005;18:720-30
   PubMed Web of Science ®Google Scholar
• Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens 2007;9:355-64
   PubMedGoogle Scholar
• Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. Curr Med Res Opinion 2009;25:315-24
   PubMed Web of Science ®Google Scholar
• Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29:279-89
   PubMed Web of Science ®Google Scholar
• Malacco E, Varì N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;11:2765-80
   Google Scholar
• Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens (Greenwich) 2008;10:185-94
   PubMed Web of Science ®Google Scholar